| Date | Time | Source | | | 05/06/2013 | 9:45AM | BW | Exactech Launches Gibralt® OCT Spinal System for Complex Cervical Thoracic Spine Procedures Now Offering Spinal Fusion Solut...
Exactech, Inc. (Nasdaq: EXAC), which designs and manufactures bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, said that its Exactech Spine division has received FDA clearance of its new Gibralt® Occipital Spine System, which includes occipital plates and 360⁰ articulating rods... More...>> |
| 04/26/2013 | 10:40AM | ZACKS | Covidien's 2Q Earnings Beat - Analyst Blog
Covidien plc.’s (COV) adjusted earnings per share (EPS) from continuing operations of $1.12 for the second quarter of fiscal 2013 beat the Zacks Consensus Estimate of $1.10 by 1.8%. It exceeded the year-ago EPS by 6.7%. Adjusted earnings exclude one-time items such as tax-related expenses, restructuring and acquisition... More...>> |
| 04/25/2013 | 7:06AM | ZACKS | Zimmer Beats Earnings, Misses Revenue - Analyst Blog
Zimmer Holdings (ZMH) reported adjusted earnings at $1.41, up 8.5% year over year, as well as a penny ahead of the Zacks Consensus Estimate. However, after including one-time items, the company reported net earnings of $218.6 million or $1.28 a share, up 4.3% or 9.4% year over year, respectively. Revenue Details In 1Q13... More...>> |
| 04/24/2013 | 5:30AM | ZACKS | Edwards Lags on Earnings & Rev - Analyst Blog
Edwards Lifesciences Corporation’s (EW) first-quarter 2013 adjusted earnings per share (EPS) came in at 72 cents, up 35.8% year over year, but lagging the Zacks Consensus Estimate of 76 cents. Adjusted EPS were also below the company-guided range of 74–78 cents. However, including a pre-tax gain of $83.6 million... More...>> |
| 04/23/2013 | 4:01PM | BW | Exactech Q1 Net Income up 17% to $3.8 Million; Diluted EPS $.29 vs. $.25; Worldwide Sales Up 1% to $59.3 Million; U.S. Sales ...
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today sales of $59.3 million for the first quarter of 2013, a 1% increase over $58.6 million in the first quarter of 2012. Net income was $3.8 million, or $0.29... More...>> |
| 04/22/2013 | 2:10PM | ZACKS | New Product from Abbott Labs - Analyst Blog
Abbott Laboratories (ABT) recently announced that the company has gained approval from the US Food and Drug Administration (FDA) for its TECNIS Toric 1-Piece intraocular lens (IOL). The company gained approval for treating cataract patients with pre-existing corneal astigmatism. Abbott Labs has launched the product following... More...>> |
| 04/19/2013 | 12:55PM | ZACKS | Abbott Labs Recalls Glucose Meter - Analyst Blog
Abbott Laboratories (ABT) recently announced that the company is initiating a voluntary recall of its FreeStyle InsuLinx Blood Glucose Meters in the US. Abbott Labs decided to recall the its FreeStyle InsuLinx Blood Glucose Meters as it found that the device displayed and stored wrong test results in patients with extremely... More...>> |
| 04/19/2013 | 12:55PM | ZACKS | Abbott Labs Recalls Glucose Meter - Analyst Blog
Abbott Laboratories (ABT) recently announced that the company is initiating a voluntary recall of its FreeStyle InsuLinx Blood Glucose Meters in the US. Abbott Labs decided to recall the its FreeStyle InsuLinx Blood Glucose Meters as it found that the device displayed and stored wrong test results in patients with extremely... More...>> |
| 04/17/2013 | 10:14AM | ZACKS | Covidien Collaborates with VIDA - Analyst Blog
International healthcare major, Covidien plc (COV) has inked an agreement with leading pulmonary imaging software service provider, VIDA Diagnostics. As per the agreement, Covidien will sell VIDA’s market-leading Apollo imaging software technology along with its i-Logic lung navigation system to advance minimally... More...>> |
| 04/17/2013 | 9:03AM | ZACKS | Abbott Reports In-Line 1Q Earnings - Analyst Blog
Abbott Laboratories (ABT) reported first quarter 2013 earnings of 42 cents per share, in line with the Zacks Consensus Estimate and 5.0% above the year-ago earnings. Including one-time items, first quarter earnings decreased 56.4% to 34 cents per share. Abbott Labs generated revenues of $5.4 billion in the first quarter... More...>> |
| 04/16/2013 | 11:34AM | BW | Exactech Schedules First Quarter 2013 Earnings Release and Conference Call
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its first quarter 2013 financial results on Tuesday, April 23, 2013. A copy of the earnings release will be available at http://www.hawkassociates.com. The company... More...>> |
| 03/18/2013 | 11:17AM | BW | Exactech to Showcase Innovations in Joint Replacement During AAOS Annual Conference in Chicago
Exactech, Inc. (Nasdaq: EXAC), which designs and manufactures bone and joint restoration products for hip, knee, shoulder and spine procedures, announced today that Exactech Chief Executive Officer Bill Petty, MD, will discuss the company’s financial highlights at Canaccord Genuity’s Musculoskeletal Conference in Chicago... More...>> |
| 02/26/2013 | 4:05PM | BW | Exactech 2012 Revenue Up 9% to $224.3M, Net Income Up 44% to $12.7M, EPS $0.96
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today that revenue for 2012 increased 9% to $224.3 million from $205.4 million in 2011. Diluted earnings per share for the year was $0.96 based on net income of $12.7 million representing... More...>> |
| 01/22/2013 | 8:15AM | BW | Exactech Announces Preliminary 2012 Sales of $224.8 Million and 4th Quarter 2012 Sales of $59.7 Million
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it expects to report revenue for the fourth quarter of 2012 of $59.7 million, an increase of 13% compared to $53.1 million for the fourth quarter of... More...>> |
| 11/20/2012 | 1:34PM | BW | In-Kind Donations Make Knee Replacement Possible for Patients in Rural Mexico
At a time many Americans devote to counting their blessings, a group of underprivileged patients in Veracruz, Mexico are thankful to be regaining the most critical aspects of rural life – their mobility and livelihood. In a hospital with a limited history of joint replacement surgeries, 12 patients experienced the spirit... More...>> |
| 11/19/2012 | 1:35PM | BW | Exactech to Present to Investors at the 24th Annual Piper Jaffray Healthcare Conference
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials will update investors and analysts at the Piper Jaffray Healthcare Conference in New York on Tuesday, November 27, 2012. The presentation session by Exactech president David... More...>> |
| 11/01/2012 | 4:40AM | ZACKS | Hanger Meets on EPS, Sales Lag - Analyst Blog
Hanger Inc.’s (HGR) reported earnings of 50 cents per share for third quarter of 2012 were in line with the Zacks Consensus Estimate. However, it exceeded the year-ago adjusted earnings of 46 cents a share (up 8.7%). Adjusted earnings exclude one-time items such as acquisition costs and expenses associated with the... More...>> |
| 10/30/2012 | 4:05PM | BW | Exactech Q3 Revenue Up 8% to $51.3M, Net Income Up 95% to $2.6M, EPS $0.19; YTD Revenue Up 8% to $165.1M, Net Income $8.9M, E...
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $51.3 million for the third quarter of 2012, an 8% increase over $47.3 million in the third quarter of 2011. Net income increased 95% to $2.6 million... More...>> |
| 10/16/2012 | 10:15AM | BW | Exactech Schedules Third Quarter 2012 Earnings Release and Conference Call
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its third quarter 2012 financial results on Tuesday, October 30, 2012. A copy of the earnings release will be available at http://www.hawkassociates.com. The... More...>> |
| 09/04/2012 | 9:00AM | ZACKS | Hanger Retained at Neutral - Analyst Blog
We reiterate our Neutral recommendation on Hanger Inc (HGR) following its second quarter results which surpassed the Zacks Consensus Estimates. The company’s adjusted earnings of 50 cents per share exceeded the year-ago earnings of 45 cents per share. Revenues rose 7.2% year over year to $251.8 million in the quarter... More...>> |
|
